Blueprint Medicines Corporation
Kathryn Haviland, serves as President, Chief Executive Officer & Director of Blueprint Medicines Corporation since 2022 and has been its Chief Operating Officer since 2019 until 2022. Ms. Haviland built relationships with key opinion leaders and patient advocacy groups and collaborated with the orphan disease community. Prior to Sarepta, she served as Executive Director of Commercial Development at PTC Therapeutics from 2007 to 2012, where she was responsible for establishing and executing PTC’s commercial strategy and building its corporate infrastructure. She held various corporate development and project management roles at Genzyme from 2005 to 2007. Ms. Haviland holds a BA in Biochemistry/Molecular Biology and Economics from Wesleyan University and an MBA from Harvard Business School.
Year appointed: 2022